MECOM and acute myeloid leukemia: In our intermediate-risk AML cohort, a panel of prognostic gene expression markers including BAALC [15], CDKN1B [15], ERG [15, 18], FLT3 [53], ID1 [17, 47], IL2RA, MN1 [15, 19], MECOM/EVI1 [46], and WT1 [54, 55] were quantified by NanoString technology.